Page 170 - Educacional Ponenecias Congreso SEHH-STH 2020

reducción la prevalencia de la ACF. Se han establecido diferentes estrategias, desde pruebas de identificación de hemoglobinopatías premaritales o preconcepcio- nales legalmente obligatorias hasta programas de cribado neonatal y campañas de educación pública.
• La menor eficacia en la reducción de nacimientos con ECF de la esperada, al igual que en otras enferme- dades genéticas, radica en la posible estigmatización de los portadores de HbAS que puede determinar una discriminación racial, laboral, económica y social, así como miedo y desconfianza en los portadores, y en el desconocimiento o la falta de implicación de los servicios sanitarios que podrían estar implicados en esta problemática.
❯ Bibliografía
1. Steinberg MH, Rodgers GP. Pathophysiology of Sickle Cell Disease: Role of Cellular and Genetic Modifiers. Semin Hematol. 2001;38:299-306.
2. Okoli K, Irani F, Horvath W. Pathophysiologic considerations for the interac- tions between obstructive sleep apnea and sickle hemoglobinopathies. Med Hypotheses. 2009 May;72(5):578-80.
3. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clini- cal epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):457-68.
4. Kotila TR. Sickle Cell Trait: A Benign State? Acta Haematol. 2016;136:147-51.
5. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet.
2010;18(10):1077-83.
6. Alswaidi FM, Memish ZA, O’Brien SJ, Al-Hamdan NA, Al-Enzy FM, et al. At risk
marriages after compulsory premarital testing and counseling for b-thalas- semia and sickle cell disease in Saudi Arabia, 2005-2006. J Genet Couns. 2012;21(2):243-55.
7. Serjeant GR, Serjeant BE, Mason KP, Gibson F, Gardner R, Warren L, Jonker M. Voluntary premarital screening to prevent sickle cell disease in Jamaica: does it work? J Community Genet. 2017;8(2):133-9.
8. Wilkie DJ, Gallo AM, Yao Y, Molokie RE, Stahl C, Hershberger PE, et al. Re- productive health CHOICES for young adults with sickle cell disease or trait: randomized controlled trial outcomes over two years. J Genet Couns. 2016;25(2):325-36.
9. Naik RP, Haywood C Jr. Sickle cell trait diagnosis: clinical and social implica- tions. Hematology Am Soc Hematol Educ Program. 2015;2015:160-7.
10. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Pro- phylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med. 1986; 314(25):1593-9.
11. Treadwell MJ, McClough L, Vichinsky E. Using qualitative and quantitative strategies to evaluate knowledge and perceptions about sickle cell disease and sickle cell trait. J Natl Med Assoc. 2006 May;98(5):704-10.
12. Kavanagh PL, Wang CJ, Therrell BL, Sprinz PG, Bauchner H. Communica- tion of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet. 2008;148C(1):15-22.
13. Farrell MH, La Pean Kirschner A,Tluczek A, Farrell PM. Experience with Parent Follow-Up for Communication Outcomes after Newborn Screening Identifies Carrier Status. J Pediatr. 2020;224:37-43.e2.
14. Hinton CF, Neuspiel DR, Gubernick RS, Geleske T, Healy J, Kemper AR, et al. Im- proving newborn screening follow-up in pediatric practices: quality improve- ment innovation network. Pediatrics. 2012 Sep;130(3):e669-75.
15. Azonobi IC, Anderson BL, Byams VR, Grant AM, Schulkin J. Obstetrician-gyne- cologists’ knowledge of sickle cell disease screening and management. BMC Pregnancy Childbirth. 2014;14:356.
16. Pecker LH, Naik RP.The current state of sickle cell trait: implications for repro- ductive and genetic counseling. Blood. 2018 Nov 29;132(22):2331-8.
17. Ashcroft MT, Desai P. Mortality and morbidity in Jamaican adults with sickle-
cell trait and with normal haemoglobin followed up for twelve years. Lancet.
1976;2(7989):784-6.
18. Castro O, Rana SR, Bang KM, Scott RB. Age and prevalence of sickle-cell trait
in a large ambulatory population. Genet Epidemiol. 1987;4(4):307-11.
19. Tsaras G, Owusu-Ansah A, Boateng FO, Amoateng-Adjepong Y. Complica- tions associated with sickle cell trait: a brief narrative review. Am J Med.
2009;122:507-12.
20. Reeves SL, Jary HK, Gondhi JP, Kleyn M, Dombkowski KJ. Health outcomes
and services in children with sickle cell trait, sickle cell anemia, and normal
hemoglobin. Blood Adv. 2019;3(10):1574-80.
21. Kark JA, Posey DM, Schumacher HR, Ruehle CJ. Sickle-cell trait as a risk factor
for sudden death in physical training. N Engl J Med. 1987;317(13):781-7. 22. Harmon KG, Drezner JA, Klossner D, Asif IM. Sickle cell trait associated with a RR of death of 37 times in National Collegiate Athletic Association football athletes: a database with 2 million athlete-years as the denominator. Br J
Sports Med. 2012;46(5):325-30.
23. Nelson DA, Deuster PA, Carter R III, Hill OT, Wolcott VL, Kurina LM. Sickle cell
trait, rhabdomyolysis, and mortality among U.S. Army soldiers. N Engl J Med.
2016;375(5):435-42.
24. Nelson DA, Deuster PA, O’Connor FG, Kurina LM. Sickle cell trait and heat
injury among US Army soldiers. Am J Epidemiol. 2018;187(3): 523-8.
25. Thompson AA. Sickle cell trait testing and athletic participation: a solu- tion in search of a problem? Hematology Am Soc Hematol Educ Program.
2013;2013:632-7.
26. ASH Statement on Screening for Sickle Cell Trait and Athletic Participation. Dis-
ponible en: http://www.hematology.org/Advocacy/Policy-Statements/7704.aspx. 27. Sitzler B. NCAA addresses exertional rhabdomyolysis. Disponible en: https://
www.nata.org/blog/beth-sitzler/ncaa-addresses-exertionalrhabdomyolysis. 28. Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black
male patients. N Engl J Med. 1979;300:1001-5.
29. Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg HM.
Framing the research agenda for sickle cell trait: building on the current un-
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
170